Development and Evaluation of Rivaroxaban Nanosus pension by Solvent Evaporation Method

Introduction: Medications that are not well soluble in water or both water and fat can be more effectively delivered with nanosuspension, as has been shown in previous studies. Traditional oral dosing forms can have their dosages reduced while still seeing improved absorption and bioavailability. Methods: A solvent evaporation method was employed to prepare a nanosuspension of rivaroxaban with the help of stabilizers such as PVP K30, PVA, poloxamer, and SLS. The revised formulation was found to have a zeta potential that falls within acceptable values. Nanosuspension formulations of Rivaroxaban were tested for goodness of fit using linear regression analysis, taking into account zero order and first-order kinetics as well as drug release equations. Results: The results showed that pure Rivaroxaban was poorly soluble in water (0.015 mg/ml) compared to other solvents, while it was more soluble in acetone. With an average particle size of 118 nm, the entrapment effectiveness varied between 82.15% and 97.31%. Researchers compared the drug release of commercially available formulation with that of manufactured nanosuspensions and found that the latter released more than 98% of the medication in just 60 minutes, while the former released just 79%. The findings of linear regression analysis using regression coefficients from the given data demonstrate that the improved formulation (F9) follows zero-order release kinetics. The strength of the Nanosuspension increased with an increase in polymer concentration, but the rate of medicine release dropped. Researchers using infrared spectroscopy found no evidence of drug-excipient interactions. Conclusion: F9 follows zero-order release kinetics and releases 99.84% of the medication in 25 minutes, making it the best formulation compared to the others.